DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
MicroCap Rodeo Fall Conference
Date: Thursday, September 25, 2025
Location: New York City
Presentation Time: 2:00 p.m. Eastern time
Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024
Lytham Partners Fall 2025 Investor Conference
Date: Tuesday, September 30, 2025
Location: Virtual
Presentation Time: 2:45 p.m. Eastern time
Webcast: https://app.webinar.net/K8vDlaelmAd
Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at aytu@lythampartners.com.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company’s prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia,…
WASHINGTON, D.C. / ACCESS Newswire / January 15, 2026 / The American Medical Informatics Association…
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a…
Multi-year wins underscore sustained specialty-first innovation, workflow depth, and revenue-cycle performance at scale TAMPA, FLORIDA…
First of its kind in the UK as medical cannabis patients get on-demand legal support…
NOTTINGHAM, UK / ACCESS Newswire / January 15, 2026 / First of its kind in…